These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 64356)

  • 1. [Serum testosterone level and excretion of androgen metabolites in patients with hypertrophy of the prostatic gland].
    Baranowska B; Migdalska B; Szymanowski J; Kozlowicz I
    Endokrynol Pol; 1977; 28(1):45-52. PubMed ID: 64356
    [No Abstract]   [Full Text] [Related]  

  • 2. [Study of the interdependence between prostatic hypertrophy and disorders in hormone levels. Preliminary report. 1. Study of blood testosterone].
    Szymanoski J; Baranowska B; Migdalska B; Kozlowicz I
    J Urol Nephrol (Paris); 1976; 82(10-11):827-36. PubMed ID: 63569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostatectomy--induced decrease in an enhanced serum testosterone concentration in patients with prostatic hyperplasia and its pathophysiological implications.
    Baranowska B; Zgliczyński S
    Endokrynol Pol; 1979; 30(1):75-87. PubMed ID: 85550
    [No Abstract]   [Full Text] [Related]  

  • 4. [Value of testosterone, FSH and LH on plasma in patients with prostatic adenoma and carcinoma before and after different hormonal treatments].
    Garcia de la Peña E; Ramos F; Horcajada C; Cifuentes Delatte L; Vivanco F
    Rev Clin Esp; 1978 Jan; 148(1):19-23. PubMed ID: 76325
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone.
    Casarosa C; Cosci di Coscio M; Fratta M
    Clin Ther; 1988; 10(5):585-8. PubMed ID: 2485240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy].
    Katayama T; Umeda K; Kazama T
    Hinyokika Kiyo; 1986 Nov; 32(11):1584-9. PubMed ID: 2435122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
    Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
    Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The influence of spironolactone on the concentration of gonadotrophins and gonadal hormones in prostatic hypertrophy (author's transl)].
    Zgliczynski S; Baranowska B; Szymanowski J
    J Urol (Paris); 1981; 87(9):635-8. PubMed ID: 6174646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of treatment with mepartricin on the plasma androgen and gonadotropin concentrations in subjects with benign prostatic hypertrophy].
    Sciarra F; Bianchi P; Toscano V
    Minerva Urol Nefrol; 1988; 40(2 Suppl):10-2. PubMed ID: 2460936
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha, 17 beta-diol, 5 alpha-androstane-3 beta, 17 beta-diol, and 17 beta-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia.
    Cochran RC; Ewing LL; Niswender GD
    Invest Urol; 1981 Nov; 19(3):142-7. PubMed ID: 6170603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hormonal disturbances in men with a prostatic adenoma (author's transl)].
    Baranowska B; Zgliczynski S; Szymanowski J
    J Urol (Paris); 1980; 86(7):551-8. PubMed ID: 6161196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
    Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal status in prostatic disease.
    Frick J; Bartsch G
    Prog Clin Biol Res; 1976; 6():143-58. PubMed ID: 66687
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of benign prostatic hyperplasia with the preparation Gentos].
    Pecherskiĭ AV; Aleksandrov VP; Mazurov VI; Kniaz'kin IV; Zeziulin PN; Nikolaeva EV
    Urologiia; 2000; (5):16-7. PubMed ID: 11392216
    [No Abstract]   [Full Text] [Related]  

  • 16. [Gonadotropic and androgenic functions in myocardial infarct].
    Tuev AV; Kasatkin IuN; Naumov AS; Ametov AS; Tupitsyna ND
    Klin Med (Mosk); 1978 Oct; 56(10):53-5. PubMed ID: 713460
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia.
    Nejishima H; Yamamoto N; Suzuki M; Furuya K; Nagata N; Yamada S
    Prostate; 2012 Oct; 72(14):1580-7. PubMed ID: 22430536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of antiestrogen, antiandrogen, and the prolactin inhibitor 2 bromo-alpha-ergocriptine on the stromal tissue of human benign prostatic hyperplasia. Correlation of stereological data and plasma hormones.
    Bartsch G; Oberholzer M; Rohr HP
    Invest Urol; 1981 Jan; 18(4):308-12. PubMed ID: 6161105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroidal compounds (injectable and implants) affecting spermatogenesis in men.
    Frick J; Bartsch G; Marberger H
    J Reprod Fertil Suppl; 1976 Sep; (24 suppl):35-47. PubMed ID: 63550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Excretion of sex hormones in prostatic adenoma].
    Shcherbakov AP; Mel'nikova IL
    Vrach Delo; 1975 Dec; (12):105-6. PubMed ID: 60003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.